文献速递糖尿病

达格列净与2型糖尿病患者肾脏疾病的预防:DECLARE-TIMI 58试验的事后分析

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.
PubMed 文献 · Diabetes Care · 2022-01-01

DECLARE-TIMI 58试验事后分析评估达格列净对2型糖尿病伴高心血管风险患者肾功能下降的影响,按KDIGO风险类别分层。多数患者处于低-中风险类别(n=15,201,90.3%)。达格列净在所有KDIGO风险类别中均降低肾脏特异性复合结局风险(P-interaction=0.97),低风险组HR 0.54(95%CI 0.38-0.77),并减缓eGFR下降斜率,提示达格列净在糖尿病肾病早期预防中的可能作用。

要点

  • 达格列净降低所有KDIGO风险类别患者的肾脏特异性复合结局风险(P-interaction=0.97)。
  • 低KDIGO风险患者中,达格列净组肾脏特异性复合结局HR 0.54(95%CI 0.38-0.77)。
  • 达格列净组eGFR各阈值下降风险均更低,低风险组eGFR斜率差异利于达格列净(P<0.0001)。

核心结论

  • 达格列净减轻2型糖尿病高心血管风险患者的肾功能下降,包括低KDIGO风险患者,提示达格列净在糖尿病肾病早期预防中的可能作用。

研究设计与样本

  • DECLARE-TIMI 58试验的事后分析,2型糖尿病高心血管风险患者随机分配至达格列净组或安慰剂组。
  • 按治疗组总体及按KDIGO风险类别分析结局,多数参与者处于低-中KDIGO风险类别(n=15,201,90.3%)。

主要发现

  • 所有KDIGO风险类别中达格列净组肾脏特异性复合结局风险更低(P-interaction=0.97),低风险组HR 0.54(95%CI 0.38-0.77)。
  • 达格列净组分类eGFR下降风险更低:≥57%(基线eGFR≥60 mL/min/1.73 m2者)HR 0.52、≥50% HR 0.57、≥40% HR 0.55、≥30% HR 0.70(P<0.05)。
  • 各KDIGO风险类别中eGFR下降斜率均利于达格列净,低KDIGO风险组组间差异慢性为0.87、总为0.55 mL/min/1.73 m2/年(P<0.0001)。

关键数值与推荐

  • 肾脏特异性复合结局:eGFR持续下降≥40%至<60 mL/min/1.73 m2、终末期肾病和肾脏相关死亡。
  • 其他结局包括不同阈值的分类eGFR下降发生率及慢性(6个月至4年)或总(基线至4年)eGFR斜率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In patients with moderate to severe albuminuric kidney disease, sodium-glucose cotransporter 2 inhibitors reduce the risk of kidney disease progression. These post hoc analyses assess the effects of dapagliflozin on kidney function decline in patients with type 2 diabetes (T2D), focusing on populations with low kidney risk. RESEARCH DESIGN AND METHODS: In the Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58) trial, patients with T2D at high cardiovascular risk were randomly assigned to dapagliflozin versus placebo. Outcomes were analyzed by treatment arms, overall, and by Kidney Disease: Improving Global Outcomes (KDIGO) risk categories. The prespecified kidney-specific composite outcome was a sustained decline ≥40% in the estimated glomerular filtration rate (eGFR) to <60 mL/min/1.73 m2, end-stage kidney disease, and kidney-related death. Other outcomes included incidence of categorical eGFR decline of different thresholds and chronic (6 month to 4 year) or total (baseline to 4 year) eGFR slopes. RESULTS: Most participants were in the low-moderate KDIGO risk categories (n = 15,201 [90.3%]). The hazard for the kidney-specific composite outcome was lower with dapagliflozin across all KDIGO risk categories (P-interaction = 0.97), including those at low risk (hazard ratio [HR] 0.54, 95% CI 0.38-0.77). Risks for categorical eGFR reductions (≥57% [in those with baseline eGFR ≥60 mL/min/1.73 m2], ≥50%, ≥40%, and ≥30%) were lower with dapagliflozin (HRs 0.52, 0.57, 0.55, and 0.70, respectively; P < 0.05). Slopes of eGFR decline favored dapagliflozin across KDIGO risk categories, including the low KDIGO risk (between-arm differences of 0.87 [chronic] and 0.55 [total] mL/min/1.73 m2/year; P < 0.0001). CONCLUSIONS: Dapagliflozin mitigated kidney function decline in patients with T2D at high cardiovascular risk, including those with low KDIGO risk, suggesting a role of dapagliflozin in the early prevention of diabetic kidney disease.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Mosenzon O, Raz I, Wiviott SD, et al. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial. Diabetes Care. 2022. PMID: 35997319. doi:10.2337/dc22-0382

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。